Will AbbVie Q2 Global Skyrizi net revenues be above __?: how this market works

What you need to know

This market is asking how much money AbbVie's drug Skyrizi will bring in globally during the second quarter of 2026, specifically whether that revenue will cross one of three dollar thresholds: $19 billion, $20 billion, or $21 billion. Skyrizi is a prescription medication used for conditions like plaque psoriasis and Crohn's disease, and it has become one of AbbVie's biggest revenue drivers. A 'Yes' on any threshold means Skyrizi's quarterly sales beat that number; a 'No' means they fell short. The market settles based on the exact Skyrizi global net revenue figure that AbbVie publishes in its official Q2 2026 earnings materials, such as a press release or regulatory filing. The number used is the most precise one reported, and later corrections do not count. AbbVie must release earnings by August 31, 2026, or everything resolves No. If Skyrizi revenue is not broken out separately in the report, that also triggers a No. No relevant news was provided for this market. The headlines available are about defense stocks, which have no connection to AbbVie or Skyrizi. To follow this market, the key thing to watch would be AbbVie's own quarterly earnings release, expected sometime in July 2026, along with any analyst forecasts or guidance updates the company issues beforehand. The main challenge is that quarterly drug revenues depend on prescription volumes, insurance coverage dynamics, competition from other treatments, and how aggressively AbbVie's sales force performs across many countries at once. All three thresholds here are priced very low, around 3 to 4 percent each, which suggests the market collectively doubts Skyrizi will reach even $19 billion in a single quarter. The honest uncertainty is simply whether something unexpected, like a major sales surge or a reporting surprise, could shift that picture before earnings drop.

The odds right now

• $22B5%
• $19B4%
• $20B3%
• $18B3%
• $21B3%

Price history

How this resolves

Resolves July 31, 2026

This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". Read the full resolution rules on the live market page.

Related

Same markets. A fraction of the fee.

These apps all route to the same exchange order book. The difference is what each one adds on top of the exchange's own fee.

Published rates, checked July 2026. MetaMask charges a flat 4 percent per prediction trade. Jupiter adds a fee equal to the exchange's own taker fee at fill time, roughly 2 to 4 percent at typical odds. Where a market carries an exchange settlement fee, it applies everywhere, whichever app you use. Paridesk adds nothing on maker orders.

Trade this market on Paridesk: non-custodial, 0.5% fee.